DrugPatentWatch Database Preview
Drugs in Development Information for Ciraparantag
» See Plans and Pricing
What is the development status for investigational drug Ciraparantag?
Ciraparantag is an investigational drug.
There have been 4 clinical trials for Ciraparantag.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2020.
The most common disease condition in clinical trials is [disabled in preview]. The leading clinical trial sponsors are Perosphere, Inc., Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., and [disabled in preview].
There are four US patents protecting this investigational drug and forty-one international patents.
Summary for Ciraparantag
| US Patents | 4 |
| International Patents | 41 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2020-11-01) |
| Vendors | 7 |
Recent Clinical Trials for Ciraparantag
| Title | Sponsor | Phase |
|---|---|---|
| Study of Ciraparantag for Reversal of Anticoagulation Induced by Apixaban or Rivaroxaban in Healthy Adults | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Phase 2 |
| Phase 2 Placebo-Controlled, Study of Apixaban Reversal by Ciraparantag as Measured by WBCT | Perosphere, Inc. | Phase 2 |
| Study of Ciraparantag Administered to Volunteers Anticoagulated With Rivaroxaban, Measure Clotting Times Using WBCT | Perosphere, Inc. | Phase 2 |
Clinical Trial Summary for Ciraparantag
Top disease conditions for Ciraparantag
Top clinical trial sponsors for Ciraparantag
US Patents for Ciraparantag
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ciraparantag | Start Trial | Anticoagulant reversal agents | PEROSPHERE INC. (Danbury, CT) | Start Trial |
| Ciraparantag | Start Trial | Anticoagulant reversal agents | PEROSPHERE INC. (Danbury, CT) | Start Trial |
| Ciraparantag | Start Trial | Stable glucagon formulations | Perosphere Inc. (Danbury, CT) | Start Trial |
| Ciraparantag | Start Trial | Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds | PEROSPHERE PHARMACEUTICALS INC. (Danbury, CT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ciraparantag
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ciraparantag | Argentina | AR089020 | 2031-11-29 | Start Trial |
| Ciraparantag | Australia | AU2012345975 | 2031-11-29 | Start Trial |
| Ciraparantag | Brazil | BR112014012892 | 2031-11-29 | Start Trial |
| Ciraparantag | Canada | CA2856540 | 2031-11-29 | Start Trial |
| Ciraparantag | Chile | CL2014001399 | 2031-11-29 | Start Trial |
| Ciraparantag | China | CN104080772 | 2031-11-29 | Start Trial |
| Ciraparantag | Colombia | CO6990738 | 2031-11-29 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
